Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.

Atevirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 and is currently in phase II clinical trials. Atevirdine is most soluble at a pH of < 2, and therefore, normal gastric acidity is most likely necessary for optimal bioavai...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Morse, G D, Fischl, M A, Shelton, M J, Borin, M T, Driver, M R, DeRemer, M, Lee, K, Wajszczuk, C P
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1996
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163195/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8851608/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.40.3.767
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!